The chromosomal region 12q13-q15 is recurrently ampli®ed in bladder cancer. Putative target genes located in this region include MDM2, CDK4, and GLI. To evaluate the involvement of these genes in bladder cancer, we screened a tissue microarray (TMA) containing 2317 samples by¯uorescence in situ hybridization (FISH). Ampli®cation was found for MDM2 in 5.1%, for CDK4 in 1.1%, and for GLI in 0.4% of interpretable tumors. Among tumors having ampli®cation of at least one of these 12q13-q15 genes, 76.6% had ampli®cation of MDM2 alone and 6.4% had ampli®cation of CDK4 alone. Coampli®cations were seen of MDM2 and CDK4 in 10.6%, and of CDK4 and GLI in 6.4%. Neither coampli®cations of all three genes nor isolated GLI ampli®cations were found. These data suggest a prominent role of MDM2 as a 12q13-q15 ampli®cation target in bladder cancer. However, independent CDK4 ampli®cations do also occur suggesting either two nonoverlapping ampli®cation sites or else a minimal overlapping region between MDM2 and CDK4 perhaps containing another yet unknown oncogene. The frequency of ampli®cation increased signi®cantly from stage pTa to pT1-4 (P50.04) and from low to high grade (P50.005). These data are consistent with a high level of genetic instability in invasively growing and highgrade bladder tumors.
Introduction
Ampli®cation is a frequent mechanism for gene overexpression in tumor cells. Amplicons can span several megabases of DNA, and numerous genes are typically included in one amplicon. This makes it dicult to de®ne which of the ampli®ed genes provide a growth advantage to tumor cells. Studies using comparative genomic hybridization (CGH) had repeatedly revealed 12q13-q15 ampli®cations in bladder cancer (Koo et al., 1999; Richter et al., 1997 Richter et al., , 1998 Simon et al., 1998 Simon et al., , 2000 Voorter et al., 1995; Zhao et al., 1999) . This genomic region contains at least 60 genes. Among these, MDM2 (murine double minutes), CDK4 (cyclin-dependent kinase 4), and GLI (glioblastoma-associated oncogene) have become the most investigated genes because of their well-known oncogenic functions. MDM2 and CDK4 play a major role in controlling the cell cycle at the G1-S checkpoint. MDM2 encodes a regulatory protein for p53 and probably other cell cycle control proteins like E2F1 (Jones et al., 1996) . CDK4 codes for a cyclin dependent kinase responsible for cell cycle progression in G1 phase (Reed, 1997) . The GLI gene acts as a transcription factor involved in vertebrate development. Ampli®cation and overexpression of these genes has been described in several tumor types including sarcoma, neuroblastoma, glioma, and breast cancer (Galanis et al., 1998; Kanoe et al., 1998; Lu et al., 1997; Masciullo et al., 1997; Momand et al., 1998) . Previous studies have suggested that alterations of MDM2 and CDK4 may be involved in bladder cancer (Habuchi et al., 1994; Lianes et al., 1994) . One of them has investigated 12q13-q15 genes on the DNA level and found MDM2 gene ampli®cation in 2 of 50 tumors (4%) (Habuchi et al., 1994) . CDK4 and GLI ampli®ca-tions have not been analysed in bladder cancer yet. To de®ne the frequency of ampli®cations and coampli®ca-tions of these genes, and to determine their associations with tumor phenotype and prognosis, we utilized our previously described tissue microarray (TMA) approach (Kononen et al., 1998; Schraml et al., 1999) . In this technique, hundreds of minute tissue samples (diameter: 0.6 mm) can be simultaneously analysed on one microscope glass slide. This allows a massively parallel high throughput in situ analysis of tissues. For the current study we used a preexisting bladder cancer TMA containing samples from 2317 tumors for uorescence in situ hybridization (FISH) analysis of MDM2, CDK4, and GLI. The data identify MDM2 as a major ampli®cation target and link 12q13-q15 ampli®cations to aggressive tumor phenotype. Figure 1b . FISH results were available for all three genes in a subset of 913 tumors. Forty-seven of these tumors (5.1%) had ampli®cations of at least one gene. Most tumors with 12q13-q15 ampli®cations (36 tumors; 76.6%) had ampli®cation of MDM2 alone (Figure 2 ). Isolated ampli®cation was rare for CDK4 (6.4%) and not found for GLI. Coampli®cation was observed for MDM2 and CDK4 in ®ve (10.6%) and for CDK4 and GLI in three tumors (6.4%). No tumor had ampli®cation of all three genes.
Results

MDM2, CDK4, and GLI amplifications
The relationship between MDM2, CDK4, or GLI ampli®cations with tumor phenotype is summarized in Table 1 . Within the subgroup of transitional cell carcinomas (TCC), MDM2 and CDK4 ampli®cations were signi®cantly linked to increasing tumor stage (P50.04) and grade (P50.005). For MDM2, the strongest dierences were found between non-invasive (pTa) and invasive (pT1 ± 4) tumors (P=0.0124). The frequency of GLI ampli®cations was too low for statistical analyses.
Gene amplification and prognosis
In order to investigate the prognostic role of gene ampli®cations, the clinically most relevant endpoints in bladder cancer were selected. These included tumor speci®c survival in all patients, tumor speci®c survival in the subgroup of muscle invasive carcinomas, tumor progression in pT1 carcinomas, and recurrences in pTa tumors. Only TCC were included for this analysis. Ampli®cations of MDM2 were not related to patient survival, neither in all tumors (P=0.3359, Figure 3a) , nor in the group of pT2 ± 4 carcinomas (P=0.3229, Figure 3b ). Also, MDM2 ampli®cation was not associated with recurrence in pTa carcinomas (P=0.5592) or progression in pT1 carcinomas (P=0.9886).
CDK4 ampli®cation was associated with shortened tumor speci®c survival in all tumors (P50.002, Figure  3c ) and this association also holds true in the group of pT2 ± 4 tumors (P50.02, Figure 3d ). The ampli®cation frequency was too low to allow comparisons between 
Expression analysis
Immunohistochemical analysis of the small test array containing MDM2 and/or CDK4 ampli®ed and nonampli®ed tumors revealed that all antibodies targeting MDM2 or CDK4 showed a strong positive staining in some tumors after protease digestion and microwave heating. However, no signi®cant staining dierences were seen between ampli®ed or nonampli®ed tumor samples and both cytoplasmic and nuclear staining was observed in most cases.
For further expression analyses, a second TMA containing 18 bladder cancer cell lines had been manufactured. Copy numbers of the MDM2 and CDK4 genes, as determined by FISH, were identical in each cell line and ranged from 2 ± 6 signals per nucleus. In addition, mRNA levels of MDM2 and CDK4 were determined in 12 of the cell lines by RT ± PCR using a Light Cycler. Similar to the primary tumors, most of the cell lines showed a strong positive staining for both MDM2 and CDK4. For both genes, there was no clear concordance between the staining intensities in IHC, the gene copy numbers, or mRNA expression levels. As an example, the data for CDK4 are summarized in Figure 4 . As a consequence of these data, no IHC were done on the large bladder cancer TMA.
Discussion
In this study, TMA technology was utilized to study ampli®cations of three known 12q13-q15 oncogenes in urinary bladder cancer. Despite the low overall frequency of ampli®cation ± only 5.1% of all tumors had ampli®cation of one or more of the oncogenes ± the high number of examined tumors allowed us to obtain a clear view of the relative importance of MDM2, CDK4, and GLI ampli®cations.
Our results strongly suggest MDM2 as the most relevant ampli®cation target among the examined genes in bladder cancer. More than 75% of tumors showing ampli®cations had an isolated MDM2 ampli®cation without involvement of CDK4 or GLI. This is dierent in sarcomas and glial tumors where coampli®cations are more frequent. For example, in tumors with 12q13-q15 ampli®cation, MDM2/CDK4 coampli®cation has been reported in 14 of 21 (67%) sarcomas, and four of them Figure 2 Coampli®cation pattern of MDM2, CDK4, and GLI. Black columns represent the frequency of independent ampli®ca-tions for MDM2 and CDK4. Gray columns indicate coampli®ca-tions between GLI and CDK4 and MDM2. Numbers and percentage refer to the subset of 47 tumors with ampli®cation of at least one of the MDM2, CDK4 or GLI Berner et al., 1996) . Similarly, Wei et al. (1999) found MDM2/CDK4 coampli®cation in ®ve of six osteosarcomas, and two of them had also ampli®cations of GLI. GLI ampli®cations are particularly frequent in gliomas and were found in eight of 22 (36%) cases with CDK4 ampli®cations, four of which showing also MDM2 coampli®cation (Reifenberger et al., 1996) . Fischer et al. (1996) reported coampli®cation of CDK4 and GLI in three of three gliomas, two of them with MDM2 coampli®cation. MDM2 being a major target of 12q13-q15 ampli®cations is consistent with the known importance of the p53 pathway in advanced urinary bladder cancer since MDM2 is an important suppressor of p53 expression (Jones et al., 1996) . MDM2 ampli®cation has been described in two of 50 tumors (4%) in a previous study (Habuchi et al., 1994) , which is in the range of our result (5.1%). A signi®cant role of MDM2 expression in bladder cancer has been suggested in several studies using immunohistochemical MDM2 analyses. Detectable MDM2 expression has been reported in 9 ± 44% of urinary bladder cancers (Ioachim et al., 2000; Jahnson and Karlsson, 2000; Korkolopoulou et al., 1997; Lianes et al., 1994; P®ster et al., 1999 Schmitz-Drager et al., 1997; Shiina et al., 1999) . Overall, these studies using immunohistochemistry have yielded con¯icting results, some of them linking MDM2 expression to high (Korkolopoulou et al., 1997) or to low (Lianes et al., 1994) grade and stage tumors while others did not ®nd an association (P®ster et al., 2000; SchmitzDrager et al., 1997; Shiina et al., 1999) . Possible explanations for these controversial data include the small numbers of analysed tumors, dierent composition of the analysed sets of tumors, as well as dierent antibodies and staining conditions. Our data also show that more than 10% of all 12q13-q15 ampli®cations did not contain the MDM2 gene. Inclusion of CDK4 in all these ampli®cations, the central function of CDKs in cell cycle and its regulation through CDKN2A (p16), another key gene in bladder cancer biology, is consistent with a primary role of CDK4 ampli®cation/overexpression in a subset of bladder cancers. Evidence for a potential oncogenic role of CDK4 overexpression is provided by several studies reporting CDK4 ampli®cation/overexpression in multiple dierent tumor types including liposarcoma (Pilotti et al., 2000; Wolf et al., 1997) , malignant ®brous histiocytoma (Gisselsson et al., 2000) , osteosarcoma (Kanoe et al., 1998) , rhabdomyosarcoma Khatib et al., 1993) , ®brosarcoma (Berner et al., 1996) , neuroblastoma , breast cancer Takano et al., 1999) , ovarian cancer (Masciullo et al., 1997) , and glial tumors (Reifenberger et al., 1996; Rollbrocker et al., 1996) . One previous study had analysed 32 transitional cell carcinomas and six bladder cancer cell lines ®nding no signi®cant dierences in the CDK4 expression level between mucosa, tumors, and cell lines (Oya et al., 1998) .
GLI ampli®cation or expression has not been reported in bladder cancer yet. Its low ampli®cation frequency and the complete lack of ampli®cations that were independent of CDK4 argue against an important role of GLI as a constituent of the 12q13-q15 amplicon in bladder cancer. Our data would be consistent with two independent amplicons centering around CDK4 and MDM2, as it was observed in several other tumor types Forus et al., 1993; Gamberi et al., 2000; Pedeutour et al., 1994; Reifenberger et al., 1996; Wei et al., 1999) . Importantly, several studies have shown that the 12q13-q15 ampli®cation can be discontinuous with gaps located between MDM2 and CDK4 (Berner et al., 1996; Elkahloun et al., 1996; Reifenberger et al., 1996; Wei et al., 1999) . Despite this, it cannot be excluded that all bladder cancers with 12q13-q15 ampli®cations found in this study contained an overlapping segment located between MDM2 and CDK4.
Our experiments do not provide sucient information to understand the anatomy of the 12q13-q15 amplicon in bladder cancer. Only three genes that were selected for their well-known importance for tumor biology were analysed within a chromosomal segment spanning approximately 13 megabases. This region between GLI and MDM2 includes as many as 61 known and another 28 predicted genes (http://www.ensembl.org). The poor association found between MDM2 and CDK4 copy numbers and mRNA or protein expression would be consistent with activation Further studies to search for other 12q13-q15 ampli®cation target genes would greatly bene®t from the availability of a large tissue bank that is linked to a TMA library. Subsequently, it would be possible to select preserved frozen tissue from tumors with the most informative FISH mapping data for RNA expression analysis.
The present study provides yet another example of the power of the TMA approach. Only 15 (3 Â 5 sections) hybridization experiments were required to acquire signi®cant data on the involvement of three putative oncogenes in the 12q13-q15 amplicon in bladder cancer. Performing this study without TMAs would have been virtually impossible because of the rarity of 12q13-q15 ampli®cations. The high number of tumors analysed in our TMA allowed searching for associations between gene ampli®cations and phenotype or clinical endpoints despite the low relative frequency of 12q13-q15 ampli®cations. The signi®cant association between gene ampli®cations and advanced tumor stage and high tumor grade was expected. Previous studies by us and others had repeatedly shown that invasively growing cancers (stage pT1 ± 4) are genetically less stable than non-invasive (pTa) tumors and that all types of chromosomal rearrangements are markedly more frequent in pT1-4 than in pTa tumors (Kallioniemi et al., 1995; Richter et al., 1997 Richter et al., , 1999 Simon et al., 1998 Simon et al., , 2000 Voorter et al., 1995; Zhao et al., 1999) . Interestingly, an association was found between CDK4 ampli®cation and tumor survival in all tumors and also in the subgroup of pT2 ± 4 cancers. However, the number of events was small in this group and further studies are required to determine the possible prognostic relevance of CDK4 alterations including expression analysis.
In summary, the results of this study show that MDM2 is a major ampli®cation target gene at 12q13-q15 and that CDK4 can be ampli®ed independently of MDM2 in about 10% of tumors with 12q ampli®ca-tions. The TMA approach enabled us to very rapidly establish associations between these rare ampli®cations and the tumor phenotype. The TMA technology will constitute an important tool to accelerate the transition from basic research ®ndings into clinical applications.
Materials and methods
Bladder cancer tissue microarray
The composition of our bladder cancer TMA containing 2317 formalin-®xed paran embedded tissues from 1853 bladder cancer patients was previously described (Richter et al., 2000) . The tumor samples were distributed on ®ve blocks each containing about 500 specimens. Some of the clinical data were updated for this study. An overview of the H&E stained microarray is shown in Figure 1a . All slides of all tumors were reviewed by one pathologist (GS). Tumor stage and grade were de®ned according to UICC and WHO (Mosto® et al., 1973; UICC, 1997) . Stage pT1 was de®ned by presence of both unequivocal tumor invasion of the suburothelial stroma and tumor-free fragments of the muscular bladder wall. Carcinomas with stroma invasion but absence of muscular bladder wall in the biopsy were classi®ed as at least pT1 (pT1-). Clinical data were available from 1123 patients. The medium follow-up period was 42 months (range 1 ± 236 months). Time to recurrence and time to progression (to stage pT2 or higher) were selected as study endpoints for patients with pTa and pT1 tumors. Follow-up information was considered complete enough to include a pTa/pT1 cancer patient in the study if cytoscopies had been performed at least at 3, 9 and 15 months, then annually until the endpoint of this study (recurrence, last control). To include a patient for analyses of time to progression, longer intervals between controls were accepted if the last follow up control ruled out progression. Recurrences were de®ned as cystoscopically visible tumors. Tumor progression was de®ned as the presence of muscle invasion (stage pT2 or higher) in a subsequent biopsy. An overview of the histological and clinical data is given in Table 2 .
For immunohistochemical analysis of MDM2 and CDK4 protein expression two small test arrays were constructed. The ®rst array contained 10 ampli®ed and 10 non-ampli®ed tumor samples selected after FISH-analysis of the 2317 samples array. The second array contained cell samples of 18 bladder cancer cell lines including HTB-1, HTB-2, HTB-3, HTB-4, HTB-5, CRL-1472, CRL-2169, CRL-7882, CRL-7588, ACC-5637, ACC-361, ACC-7930, HB-CLS-1, HB-CLS-439, RT-112, RT-112-D21, EJ-28, and KU-1919 .
Fluorescence in situ hybridization (FISH)
The tissue microarray sections of both the 2317 samples bladder cancer array and of the 18 samples cell lines array were treated according to the Paran Pretreatment Reagent Kit protocol (Vysis, IL, USA) before hybridization. FISH was performed with a Spectrum Orange-labeled MDM2 (BAC clone with 144 kb insert), CDK4 (BAC clone with 155 kb insert), or GLI (P1 clone with 70 kb insert) probe, each in combination with a Spectrum Green-labeled chromosome 12 centromeric probe (Vysis, IL, USA, Cat.# 32-160012) as a reference. All locus speci®c probes were obtained from Vysis, Illinois, but are not commercially available at present. Hybridization and posthybridization washes were according to the`LSI procedure' (Vysis, Illinois). Slides were then counterstained with 125 ng/ml 4',6-diamino-2-phenylindole in antifade solution. Ampli®cation was de®ned as presence of at least three times more gene signals than centromere 12 signals in at least 10% of nuclei.
Immunohistochemistry
Standard indirect immunoperoxidase procedures were used for immunohistochemistry (ABC-Elite, Vector Laboratories, Burlingame, CA, USA). Three dierent monoclonal antibodies against MDM2 (NCL-MDM2, Novocastra/SMP 14, DAKO/SMP 14, Santa Cruz) and four antibodies against CDK4 (C-22-G, Santa Cruz/mouse anti cdk4, Chemicon/ DCS-156, Progen/DCS-35, Progen) were tested at various pretreatment conditions and antibody dilutions.
mRNA expression analysis
Levels of MDM2 and CDK4 mRNA were determined by RT ± PCR in 12 of the 18 bladder cancer cell lines using a LightCycler TM (Roche, Rotkreuz, Switzerland) . In brief, 0.5 mg of mRNA from each bladder cancer cell line was used to generate cDNA using Superscript First-Strand Synthesis System (Invitrogen, Carlsbad, CA 92008, USA) according to the manufacturer's instructions. MDM2-speci®c primers (forward primer 5'-GGGAGATATGTTGTGAAA-GAAGC-3' and reverse primer 5'-CCCTGCCTGATACA-CAGTAACTT-3' yielding a 244 bp PCR product) and CDK4-speci®c primers (forward primer 5'-CAGGACC-TAAGGACATATCTGGA-3' and reverse primer 5'-CTCGGTACCAGAGTGTAACAACC-3' yielding a 253 bp PCR product) as well as b-actin-speci®c primers (forward primer 5'-ATTAAGGAGAAGCTGTGCTACGTC-3' and reverse primer 5'-ATGATCTTGATCTTCATTGTGCTG-3') were used for analysis of gene expression levels. The PCR mixture contained 5 ml of the diluted cDNA (1 : 50), 2 ml LCFastStart DNA Master SYBR Green 1 reaction mixture (Roche, Indianapolis, IN, USA), 3 mM MgCl 2 , and 0.5 mM of each primer in a ®nal volume of 20 ml. The PCR cycling conditions were performed as follows: initial denaturation for 10 min at 958C; 35 cycles (MDM2: 40 cycles) with denaturation at 958C for 15 s, annealing at 608C for 5 s, and extension at 728C for 12 s; followed by a ®nal extension at 758C for 15 s. Relative gene expression was quanti®ed by de®ning noise band, log-linear lines of the ampli®cation curves, and crossing point values. The speci®city of PCR products was determined by melting curve analysis. The relative gene expression levels were determined by calculating the ratios of the crossing point values of MDM2 and CDK4 versus b-Actin.
Statistics
Only the ®rst biopsy of patients having more than one tumor in the array was used for statistical analyses. Contingency table analysis and Chi-square tests were used to study the relationship between histologic tumor type, grade, stage and gene ampli®cation. Survival curves were plotted according to Kaplan ± Meier. A log rank test was applied to examine the relationship between grade, stage or gene ampli®cations and tumor recurrence, progression, or survival. For the analysis of time to recurrence or progression, patients with pTa/pT1 tumors were censored at the time of their last clinical control showing no evidence of disease or at the date when cystectomy was performed. For survival analysis, patients were censored at the time of their last clinical control or at the time of death if they died from causes not related to their tumor.
